Cargando…

New insight of metabolomics in ocular diseases in the context of 3P medicine

Metabolomics refers to the high-through untargeted or targeted screening of metabolites in biofluids, cells, and tissues. Metabolome reflects the functional states of cells and organs of an individual, influenced by genes, RNA, proteins, and environment. Metabolomic analyses help to understand the i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Quyan, Wang, Nan, Rui, Yuhua, Xia, Yang, Xiong, Siqi, Xia, Xiaobo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971428/
https://www.ncbi.nlm.nih.gov/pubmed/36866159
http://dx.doi.org/10.1007/s13167-023-00313-9
_version_ 1784898095806414848
author Zhang, Quyan
Wang, Nan
Rui, Yuhua
Xia, Yang
Xiong, Siqi
Xia, Xiaobo
author_facet Zhang, Quyan
Wang, Nan
Rui, Yuhua
Xia, Yang
Xiong, Siqi
Xia, Xiaobo
author_sort Zhang, Quyan
collection PubMed
description Metabolomics refers to the high-through untargeted or targeted screening of metabolites in biofluids, cells, and tissues. Metabolome reflects the functional states of cells and organs of an individual, influenced by genes, RNA, proteins, and environment. Metabolomic analyses help to understand the interaction between metabolism and phenotype and reveal biomarkers for diseases. Advanced ocular diseases can lead to vision loss and blindness, reducing patients’ quality of life and aggravating socio-economic burden. Contextually, the transition from reactive medicine to the predictive, preventive, and personalized (PPPM / 3P) medicine is needed. Clinicians and researchers dedicate a lot of efforts to explore effective ways for disease prevention, biomarkers for disease prediction, and personalized treatments, by taking advantages of metabolomics. In this way, metabolomics has great clinical utility in the primary and secondary care. In this review, we summarized much progress achieved by applying metabolomics to ocular diseases and pointed out potential biomarkers and metabolic pathways involved to promote 3P medicine approach in healthcare.
format Online
Article
Text
id pubmed-9971428
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-99714282023-03-01 New insight of metabolomics in ocular diseases in the context of 3P medicine Zhang, Quyan Wang, Nan Rui, Yuhua Xia, Yang Xiong, Siqi Xia, Xiaobo EPMA J Review Metabolomics refers to the high-through untargeted or targeted screening of metabolites in biofluids, cells, and tissues. Metabolome reflects the functional states of cells and organs of an individual, influenced by genes, RNA, proteins, and environment. Metabolomic analyses help to understand the interaction between metabolism and phenotype and reveal biomarkers for diseases. Advanced ocular diseases can lead to vision loss and blindness, reducing patients’ quality of life and aggravating socio-economic burden. Contextually, the transition from reactive medicine to the predictive, preventive, and personalized (PPPM / 3P) medicine is needed. Clinicians and researchers dedicate a lot of efforts to explore effective ways for disease prevention, biomarkers for disease prediction, and personalized treatments, by taking advantages of metabolomics. In this way, metabolomics has great clinical utility in the primary and secondary care. In this review, we summarized much progress achieved by applying metabolomics to ocular diseases and pointed out potential biomarkers and metabolic pathways involved to promote 3P medicine approach in healthcare. Springer International Publishing 2023-02-17 /pmc/articles/PMC9971428/ /pubmed/36866159 http://dx.doi.org/10.1007/s13167-023-00313-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review
Zhang, Quyan
Wang, Nan
Rui, Yuhua
Xia, Yang
Xiong, Siqi
Xia, Xiaobo
New insight of metabolomics in ocular diseases in the context of 3P medicine
title New insight of metabolomics in ocular diseases in the context of 3P medicine
title_full New insight of metabolomics in ocular diseases in the context of 3P medicine
title_fullStr New insight of metabolomics in ocular diseases in the context of 3P medicine
title_full_unstemmed New insight of metabolomics in ocular diseases in the context of 3P medicine
title_short New insight of metabolomics in ocular diseases in the context of 3P medicine
title_sort new insight of metabolomics in ocular diseases in the context of 3p medicine
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971428/
https://www.ncbi.nlm.nih.gov/pubmed/36866159
http://dx.doi.org/10.1007/s13167-023-00313-9
work_keys_str_mv AT zhangquyan newinsightofmetabolomicsinoculardiseasesinthecontextof3pmedicine
AT wangnan newinsightofmetabolomicsinoculardiseasesinthecontextof3pmedicine
AT ruiyuhua newinsightofmetabolomicsinoculardiseasesinthecontextof3pmedicine
AT xiayang newinsightofmetabolomicsinoculardiseasesinthecontextof3pmedicine
AT xiongsiqi newinsightofmetabolomicsinoculardiseasesinthecontextof3pmedicine
AT xiaxiaobo newinsightofmetabolomicsinoculardiseasesinthecontextof3pmedicine